Sign In
Buy KNBWY
$16.48
+0.270 (+1.67%)
At Close: Jun 03, 2026
Kirin Holdings: Conducting Human Rights Due Diligence For Sustainable Sourcing Of Sri Lankan Tea Leaves
01:26am, Friday, 31'st Jan 2025
TOKYO--(BUSINESS WIRE)--Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO:2503) and Mitsui Norin Co., Ltd. (Mitsui Norin) are developing a human rights due diligence initiative targeting tea pla
GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the C
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
10:00am, Tuesday, 28'th Jan 2025
Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and development Longstanding relationship str
KNBWY vs. DEO: Which Stock Is the Better Value Option?
12:41pm, Monday, 27'th Jan 2025
Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Kirin Holdings Co. (KNBWY) and Diageo (DEO). But which of these two companies is the best option for t
Should Value Investors Buy Kirin (KNBWY) Stock?
10:41am, Monday, 27'th Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
08:00pm, Monday, 09'th Dec 2024
BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases w
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
07:00am, Monday, 09'th Dec 2024
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
05:52pm, Wednesday, 20'th Nov 2024
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
05:00pm, Wednesday, 20'th Nov 2024
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – �
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
02:40am, Thursday, 31'st Oct 2024
TOKYO--(BUSINESS WIRE)--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will
Kirin Holdings: More Patience Is Required
04:25pm, Wednesday, 09'th Oct 2024
My Hold rating for Kirin Holdings is unchanged due to the company's mixed progress relating to diversification beyond the core beverages business, with the pharmaceuticals business growing well and Ky
GALASHIELS & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim find
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
07:00am, Wednesday, 25'th Sep 2024
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET P
One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO , Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co.,
KNBWY or DEO: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 28'th Aug 2024
Investors interested in Beverages - Alcohol stocks are likely familiar with Kirin Holdings Co. (KNBWY) and Diageo (DEO). But which of these two stocks is more attractive to value investors?
